Researchers a step closer to controlling inflammation in MS

October 4, 2012

(Medical Xpress)—A University of Adelaide researcher has published results that suggest a possible new mechanism to control multiple sclerosis (MS).

Dr Iain Comerford from the University's School of Molecular and Biomedical Science earned a three-year fellowship from Australia to work on this project. It is directed towards understanding how specific enzymes in cells of the immune system regulate immune cell activation and migration.

Along with his colleagues, Professor Shaun McColl and PhD students Wendel Litchfield and Ervin Kara, he focused on a molecule known as PI3Kgamma, which is involved in the activation and movement of .

"There's already been worldwide interest in PI3Kgamma in relation to other human inflammatory disorders, such as diabetes and , and our study links this molecule and MS," said Dr Comerford, who is a Multiple Sclerosis Research Australia Fellow at the University of Adelaide.

Dr Comerford and his colleagues have now shown that this molecule is crucial for the development of experimental autoimmune encephalitis (EAE) in an developed as a standard laboratory system for studying MS.

The team showed that a , which knocked out that particular molecule, resulted in a high resistance to the development of EAE and therefore protected against the nervous system damage typical of multiple sclerosis.

When the molecule is present, severe damage to the insulating myelin in the central nervous system was evident, resulting in inflammation in the spinal cord and myelin loss.

Following up on this result, the team then used an orally active drug that blocks the activity of the molecule PI3Kgamma at the first signs of disease onset. The drug even suppressed the development of EAE and reversed clinical signs of the disease.

"Our results so far have been very promising," Dr Comerford said.

"We've shown that by blocking PI3Kgamma, we can reduce the activation of self-reactive immune cells, reduce the release of inflammation-inducing from immune cells, and also result in a dramatic reduction in the movement of into the central nervous system.

"Our hope is that future therapies for MS might target this molecule, which could very specifically dampen the damaging inflammation in the .

"It will now be crucial to determine whether targeting these molecules could be a safe and effective way to treat MS in humans," Dr Comerford said.

Mr Jeremy Wright, CEO of MS Research Australia said: "It is very rewarding to see that MSRA has been able to support these exciting developments by a young up-and-coming researcher. We will await his further results with great interest," he said.

The research results were published recently in the online journal PLOS ONE.

Explore further: Blocking crucial molecule could help treat multiple sclerosis

More information: www.plosone.org/article/info%3 … journal.pone.0045095

Related Stories

Blocking crucial molecule could help treat multiple sclerosis

April 24, 2011
Reporting in Nature Immunology, Jefferson neuroscientists have identified a driving force behind autoimmune diseases such as multiple sclerosis (MS), and suggest that blocking this cell-signaling molecule is the first step ...

Multiple sclerosis: Damaged myelin not the trigger

February 27, 2012
Damaged myelin in the brain and spinal cord does not cause the autoimmune disease multiple sclerosis (MS), neuroimmunologists from the University of Zurich have now demonstrated in collaboration with researchers from Berlin, ...

Receptor may hold key to multiple sclerosis treatment

June 11, 2012
(Medical Xpress) -- A receptor recently discovered to control the movement of immune cells across central nervous system barriers (including the blood-brain barrier) may hold the key to treating multiple sclerosis (MS), a ...

Recommended for you

Study confirms link between the number of older brothers and increased odds of being homosexual

December 12, 2017
Groundbreaking research led by a team from Brock University has further confirmed that sexual orientation for men is likely determined in the womb.

Time of day affects severity of autoimmune disease

December 12, 2017
Insights into how the body clock and time of day influence immune responses are revealed today in a study published in leading international journal Nature Communications. Understanding the effect of the interplay between ...

Team identifies DNA element that may cause rare movement disorder

December 11, 2017
A team of Massachusetts General Hospital (MGH) researchers has identified a specific genetic change that may be the cause of a rare but severe neurological disorder called X-linked dystonia parkinsonism (XDP). Occurring only ...

Protein Daple coordinates single-cell and organ-wide directionality in the inner ear

December 11, 2017
Humans inherited the capacity to hear sounds thanks to structures that evolved millions of years ago. Sensory "hair cells" in the inner ear have the amazing ability to convert sound waves into electrical signals and transmit ...

Gene therapy improves immunity in babies with 'bubble boy' disease

December 9, 2017
Early evidence suggests that gene therapy developed at St. Jude Children's Research Hospital will lead to broad protection for infants with the devastating immune disorder X-linked severe combined immunodeficiency disorder. ...

In lab research, scientists slow progression of a fatal form of muscular dystrophy

December 8, 2017
In a paper published in the Nature journal Scientific Reports, Saint Louis University (SLU) researchers report that a new drug reduces fibrosis (scarring) and prevents loss of muscle function in an animal model of Duchenne ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.